Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

The road to recovery wasn’t an easy one for Dave Coulier. Recently the “Full House” star, 65, revealed he was hospitalized ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

I just hope, and I pray that... it isn't as harsh on her as it has been on me...,” Chelsea Martinez said of her grandmother's ...

Last month, “Full House” actor Dave Coulier became cancer-free after being diagnosed with Stage 3 Non-Hodgkin Lymphoma in ...

ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.